Neurocrine Biosciences, Inc. (NBIX) Stock Analysis & Investment Frameworks
Neurocrine Biosciences, Inc. (NBIX) stock analysis on Invetso. Review Neurocrine Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Neurocrine Biosciences, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Neurocrine Biosciences, Inc. Key Financial Metrics
- Market Cap: $16.17B
- Revenue: $2.86B
- P/E Ratio: 33.78
- ROE: 19.74%
- ROIC: 14.30%
- Dividend Yield: N/A
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Neurocrine Biosciences, Inc. Investment Frameworks
Invetso analyzes Neurocrine Biosciences, Inc. (NBIX) across the following frameworks:
- Neurocrine Biosciences, Inc. 10Y Growth Potential
- Neurocrine Biosciences, Inc. Scenario Analysis
- Neurocrine Biosciences, Inc. Risks & Opportunities
- Neurocrine Biosciences, Inc. Economic Moat
- Neurocrine Biosciences, Inc. Business Model
- Neurocrine Biosciences, Inc. Management
- Neurocrine Biosciences, Inc. SWOT Analysis
- Neurocrine Biosciences, Inc. Porter's 5 Forces
- Neurocrine Biosciences, Inc. PESTLE Analysis
- Neurocrine Biosciences, Inc. ESG Analysis